On November 30, 2012, the Supreme Court agreed to hear the plaintiffs' appeal of the Federal Circuit's ruling. In June 2013, in "Association for Molecular Pathology v. Myriad Genetics" (No. 12-398), the court unanimously ruled that, "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated," invalidating Myriad's patents on the BRCA1 and BRCA2 genes. However, the Court also held synthesized DNA sequences, not occurring in nature, can still be eligible for patent protection.